CheckMate 77T

Prespecified interim analysis results from CheckMate 77T trial of neoadjuvant nivolumab or placebo plus chemotherapy and adjuvant nivolumab or placebo in stage II to IIIB NSCLC, as presented at ESMO Congress 2023 and reported by Clinical Care Options (CCO)

ESMO Abstract Leak Reveals Promising NSCLC Therapies from BMS

Dipesh Uprety MD FACP on X: CheckMate-77T #ESMO23 @ESMO

Canakinumab with and without pembrolizumab in patients with

Shaheenah Dawood on LinkedIn: #nsclc #oncologyresearch

Shaheenah Dawood on LinkedIn: On March 4 2022, the FDA approved

Stephen V Liu, MD on X: #ESMO23 Dr. Tina Cascone presents the

Pre- and Postsurgical Immunotherapy Improves Outcomes in Operable

CheckMate-77T Trial Meets Primary EFS End Point in Resectable NSCLC

Evolution of Combination Therapies for Clinical Stage IIIA Non